Company Encyclopedia
View More
name
NovaBridge Biosciences
NBP.US
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc.
1.945 T
NBP.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    NovaBridge will present new data on ragistomig at ESMO-IO with Abstract #688 by co-developer ABL Bio on Dec 10th at 5:30 PM.

    NovaBridge Biosciences (Nasdaq: NBP), a biotechnology platform company, announced new data from the expanded Phase 1 dosing study of ragistomig, a 4-1BB X PD-L1 bispecific antibody. The data will be presented at the ESMO-IO 2025 by ABL Bio. Poster (Abstract #688) to be presented by Gerald Falchook, MD, Director of Sarah Cannon Research Institute at HealthONE Denver, on December 10th at 5:30 PM GMT.

    Unusual Whales·
    US
    NBP
    +4.76%
    Unusual Whales·
    US
    NBP
    +4.76%

    NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward | NBP Stock News

    NovaBridge Biosciences' subsidiary, Visara, has appointed Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board. These appointments aim to advance the VIS-101 program, a novel bifunctional biologic targeting VEGF-A/ANG2, expected to be Phase-3-ready in 2026. The appointments highlight Visara's commitment to building a world-class team and advancing innovative ophthalmology treatments.

    StockTitan·
    US
    NBP
    +4.76%
    StockTitan·
    US
    NBP
    +4.76%

    NovaBridge Biosciences Pursues Hong Kong Listing Amid Strategic Shift

    NovaBridge Biosciences has applied for a dual primary listing on the Hong Kong Stock Exchange and an IPO of its ordinary shares as part of a strategic shift to a new business model. The company aims to advance therapeutic assets through partnerships and subsidiaries. Recent developments include a Series A Preferred Stock Subscription Agreement with Visara and a completed safety assessment for a Phase 1b clinical trial of givastomig. Analyst ratings for I-MAB stock show a Buy with a $7.00 price target, but concerns about financial challenges and ongoing losses persist.

    Tip Ranks·
    US
    NBP
    +4.76%
    Tip Ranks·
    US
    NBP
    +4.76%

    I-Mab Files for Dual Primary Listing on Hong Kong Stock Exchange

    I-Mab NovaBridge Biosciences has filed for a dual primary listing of its ordinary shares on the Hong Kong Stock Exchange, with an accompanying initial public offering. The shares have a par value of US$0.0001 each. This announcement is for informational purposes and should not be considered financial or legal advice.

    Reuters·
    US
    NBP
    +4.76%
    US
    IMAB
    0.00%
    Reuters·
    US
    NBP
    +4.76%
    US
    IMAB
    0.00%

    I-Mab Subsidiary Visara Assigns VIS-101 License to Everest Medicines

    I-Mab's subsidiary Visara has assigned its exclusive license for VIS-101 to Everest Medicines. This agreement allows Everest Medicines to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and select Southeast Asian countries. The information was originally published by I-Mab via EDGAR on October 30, 2025.

    Reuters·
    US
    IMAB
    0.00%
    HK
    01952
    +0.22%
    US
    NBP
    +4.76%
    Reuters·
    US
    IMAB
    0.00%
    HK
    01952
    +0.22%
    US
    NBP
    +4.76%
    © 2025 Longbridge｜Disclaimer